Advanced Filters
noise

Esophageal Disorders Clinical Trials

A listing of Esophageal Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 717 clinical trials
B Bin Li, MD

Incidence of 106TBL Lymph Node Metastasis

the study was to document the incidence of left tracheobronchial lymph node metastasis, and the risk factors of metastasis.

20 - 85 years of age All Phase N/A
C Chen Haiquan, MD

Incidence of 107 Lymph Node Metastasis

the study was to document the incidence o subcarinal lymph node metastasis, and the risk factors of metastasis.

20 - 85 years of age All Phase N/A
J Jang-Ming Lee

ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients

Alcohol consumption, smoking, and betel nut chewing have been proven to be closely associated with the risk of esophageal cancer (EC). Recent studies have shown that alcohol-related detoxification genes in the ALDH family influence individual susceptibility to esophageal cancer. Aldehyde dehydrogenase 2 (ALDH2) is one of the most important enzymes …

18 - 99 years of age Male Phase N/A

Perioperative SDD to Prevent Infectious Complications After Esophagectomy

The primary aim of the PERSuaDER-trial is to evaluate the effect of SDD on infectious complications after esophagectomy, focussed on the prevention of pneumonia

18 years of age All Phase 3
K Kuaile Zhao

Precision Palliative Care for Patients With Advanced Esophageal Cancer

The goal of this clinical trial is to learn if precision palliative care improves survival of patients with advanced esophageal cancer in adults. Researchers will compare precision palliative care and standard palliative care to see if precision palliative care works more effectively to treat advanced esophageal s cancer. Participants will …

18 years of age All Phase N/A

Treatment Outcomes of Esophageal Cancer

This study will be a carried out through a prospective observational cohort design in conjunction with researchers in the African Esophageal Cancer Consortium (AfrECC). The purpose of this research is to prospectively evaluate outcomes related to existing treatment strategies for esophageal cancer (EC) at participating sites within AfrECC.

18 years of age All Phase N/A
V V. Raman Muthusamy, MD

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).

18 - 100 years of age All Phase N/A
J Julie A. Ward, BSN

Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life

To assess short and long term outcomes after minimally invasive esophagectomy compared to open esophagectomy. To compare both standard outcome measures as well as patient derived outcome measures, in particular, quality of life (QOL). To look at the applicability of this QOL instrument to this patient group.

18 years of age All Phase N/A

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal …

18 years of age All Phase 1/2

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, …

18 years of age All Phase 1/2

Simplify language using AI